Outlier in a BE study [Outliers]

posted by Helmut Homepage – Vienna, Austria, 2014-01-16 15:54 (3746 d 08:01 ago) – Posting: # 12181
Views: 9,388

Hi Kumar,

❝ FDA does not encourage redosing to handle outliers subjects incase of non-replicate design study…


Correct.

❝ … wherein you may carry out redosing incase of replicate design.


I don’t think so – at least in a fully replicated design (see this post). In a partial replicate – if the “outlier” occurred after T – I would not perform a re-dosing study without contacting FDA OGD’s review stuff beforehand.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,654 registered users;
89 visitors (0 registered, 89 guests [including 3 identified bots]).
Forum time: 00:55 CEST (Europe/Vienna)

The only way to comprehend what mathematicians mean by Infinity
is to contemplate the extent of human stupidity.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5